CytRx (CYTR) Will Present Aldoxorubicin Phase 1b/2 Data at CTOS Annual Meeting
Tweet Send to a Friend
CytRx (Nasdaq: CYTR) announced that a poster titled "A Phase 1b/2 Study of Aldoxorubicin plus Ifosfamide/Mesna in Untreated Sarcoma Patients ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
